Corcept Therapeutics (CORT)
NASDAQ:CORT
Want to see CORT full AI Analyst Report?
Total Valuation
Corcept Therapeutics has a market cap or net worth of $7.80B. The enterprise value is $7.36B.
Market Cap$7.80B
Enterprise Value$7.36B
Share Statistics
Corcept Therapeutics has 107,351,590 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding107,351,590
Owned by Insiders10.90%
Owned by Institutions16.28%
Financial Efficiency
Corcept Therapeutics’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 6.67%.
Return on Equity (ROE)0.15
Return on Assets (ROA)0.12
Return on Invested Capital (ROIC)6.67%
Return on Capital Employed (ROCE)0.07
Revenue Per Employee1.52M
Profits Per Employee196.34K
Employee Count500
Asset Turnover0.91
Inventory Turnover1.01
Valuation Ratios
The current PE Ratio of Corcept Therapeutics is 163.3. Corcept Therapeutics’s PEG ratio is -1.22.
PE Ratio163.3
PS Ratio4.75
PB Ratio5.58
Price to Fair Value5.58
Price to FCF25.49
Price to Operating Cash Flow65.12
PEG Ratio-1.22
Income Statement
In the last 12 months, Corcept Therapeutics had revenue of 761.41M and earned 99.65M in profits. Earnings per share was 0.95.
Revenue761.41M
Gross Profit748.43M
Operating Income44.80M
Pretax Income66.46M
Net Income99.65M
EBITDA46.69M
Earnings Per Share (EPS)0.95
Cash Flow
In the last 12 months, operating cash flow was 120.10M and capital expenditures -308.00K, giving a free cash flow of 119.79M billion.
Operating Cash Flow120.10M
Free Cash Flow119.79M
Free Cash Flow per Share1.12
Dividends & Yields
Corcept Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.51
52-Week Price Change7.60%
50-Day Moving Average51.09
200-Day Moving Average59.48
Relative Strength Index (RSI)87.95
Average Volume (3m)1.17M
Important Dates
Corcept Therapeutics upcoming earnings date is Aug 5, 2026, TBA (Confirmed).
Last Earnings DateApr 30, 2026
Next Earnings DateAug 5, 2026
Ex-Dividend Date―
Financial Position
Corcept Therapeutics as a current ratio of 2.92, with Debt / Equity ratio of 1.51%
Current Ratio2.92
Quick Ratio2.85
Debt to Market Cap<0.01
Net Debt to EBITDA-2.45
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Corcept Therapeutics has paid -33.19M in taxes.
Income Tax-33.19M
Effective Tax Rate-0.50
Enterprise Valuation
Corcept Therapeutics EV to EBITDA ratio is 74.97, with an EV/FCF ratio of 24.69.
EV to Sales4.60
EV to EBITDA74.97
EV to Free Cash Flow24.69
EV to Operating Cash Flow24.65
Balance Sheet
Corcept Therapeutics has $338.18M in cash and marketable securities with $9.64M in debt, giving a net cash position of $328.55M billion.
Cash & Marketable Securities$338.18M
Total Debt$9.64M
Net Cash$328.55M
Net Cash Per Share$3.06
Tangible Book Value Per Share$6.24
Margins
Gross margin is 98.25%, with operating margin of 5.88%, and net profit margin of 13.09%.
Gross Margin98.25%
Operating Margin5.88%
Pretax Margin8.73%
Net Profit Margin13.09%
EBITDA Margin6.13%
EBIT Margin5.88%
Analyst Forecast
The average price target for Corcept Therapeutics is $97.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$97.50
Price Target Upside111.22% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast12.20%
EPS Growth Forecast-64.76%